ATE488249T1 - Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung - Google Patents

Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung

Info

Publication number
ATE488249T1
ATE488249T1 AT02748276T AT02748276T ATE488249T1 AT E488249 T1 ATE488249 T1 AT E488249T1 AT 02748276 T AT02748276 T AT 02748276T AT 02748276 T AT02748276 T AT 02748276T AT E488249 T1 ATE488249 T1 AT E488249T1
Authority
AT
Austria
Prior art keywords
hsv
herpes simplex
simplex virus
amino acids
fragment
Prior art date
Application number
AT02748276T
Other languages
German (de)
English (en)
Inventor
David Koelle
Nancy Hosken
Christine Posavad
Hongbo Chen
Patrick Mcgowan
Original Assignee
Univ Washington
Corixa Corp
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Corixa Corp, Hutchinson Fred Cancer Res filed Critical Univ Washington
Application granted granted Critical
Publication of ATE488249T1 publication Critical patent/ATE488249T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02748276T 2001-07-31 2002-07-31 Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung ATE488249T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30892301P 2001-07-31 2001-07-31
US30942801P 2001-08-01 2001-08-01
PCT/US2002/024306 WO2003011893A2 (en) 2001-07-31 2002-07-31 Immunologically significant herpes simplex virus antigens and methods for using same

Publications (1)

Publication Number Publication Date
ATE488249T1 true ATE488249T1 (de) 2010-12-15

Family

ID=26976523

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02748276T ATE488249T1 (de) 2001-07-31 2002-07-31 Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung

Country Status (8)

Country Link
US (2) US6814969B2 (https=)
EP (2) EP1420821B8 (https=)
JP (1) JP4519461B2 (https=)
AT (1) ATE488249T1 (https=)
AU (1) AU2002317604A1 (https=)
CA (1) CA2454750C (https=)
DE (1) DE60238330D1 (https=)
WO (1) WO2003011893A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1523582T3 (da) * 2002-07-18 2009-03-02 Univ Washington Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved
JP2007505147A (ja) 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン
US7723308B2 (en) 2005-04-15 2010-05-25 Human Matrix Sciences, Llc Plant-derived elastin binding protein ligands and methods of using the same
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
EP2521786B1 (en) 2006-07-20 2015-06-24 Vical Incorporated Compositions for vaccinating against hsv-2
KR101352238B1 (ko) 2007-04-04 2014-01-15 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 단순포진바이러스 감염 치료를 위한 비특이적 지연형 과민증 반응
CA2700808C (en) 2007-09-27 2017-11-14 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
ES2524699T3 (es) * 2008-06-05 2014-12-11 Immunovaccine Technologies Inc. Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
WO2010115172A2 (en) 2009-04-03 2010-10-07 University Of Washington Antigenic peptide of hsv-2 and methods for using same
EP3756684A1 (en) 2009-05-22 2020-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US20130224236A1 (en) * 2010-11-03 2013-08-29 University Of Washington Hsv-1 epitopes and methods for using same
EP2643014A4 (en) 2010-11-24 2015-11-11 Genocea Biosciences Inc HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
JP6240077B2 (ja) 2011-10-06 2017-11-29 イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. Tlr2を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
EP2782597B1 (en) 2011-11-23 2022-04-13 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
KR102136433B1 (ko) 2012-05-16 2020-07-22 이뮨 디자인 코포레이션 Hsv-2 백신
KR102533463B1 (ko) 2015-02-26 2023-05-16 스퀘어렉스 파마슈티컬 코포레이션 단순 포진 바이러스 감염을 치료하기 위한 비특이적 지연형 과민성 반응
CA3017555A1 (en) * 2016-03-14 2017-09-21 Redbiotec Ag Means and methods for treating hsv
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ, インコーポレイテッド ヘルペスを処置するための方法および組成物
WO2019018796A1 (en) * 2017-07-21 2019-01-24 Fred Hutchinson Cancer Research Center VACCINE EPITOPES AGAINST HERPES SIMPLEX VIRUS RECOGNIZED SPECIFICALLY BY MEMORY T LYMPHOCYTES RESIDING IN FABRICS
CN112710849A (zh) * 2020-12-24 2021-04-27 首都医科大学附属北京友谊医院 一种鉴定抗EBV免疫活性的ELISpot试剂盒、制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0541692B1 (en) 1990-08-02 1999-05-06 Chiron Corporation Herpes simplex virus vp16 vaccines
CA2090295A1 (en) 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
BR9610058A (pt) 1995-07-28 1999-07-27 Marie Curie Cancer Care Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células
GB9615726D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Anti-viral agent 11
CA2270282A1 (en) 1996-11-04 1998-05-14 Smithkline Beecham Corporation Novel coding sequences from herpes simplex virus type-2
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
CA2291010A1 (en) 1997-06-02 1998-12-10 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
DK2272859T3 (en) 1998-08-07 2015-01-19 Univ Washington Immunological herpes simplex virus antigens and methods for their use
HK1044799A1 (zh) * 1999-09-30 2002-11-01 University Of Washington 免疫学上重要的单纯疱疹病毒抗原
ATE349533T1 (de) * 2000-06-29 2007-01-15 Corixa Corp Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection

Also Published As

Publication number Publication date
CA2454750A1 (en) 2003-02-13
JP2004537308A (ja) 2004-12-16
JP4519461B2 (ja) 2010-08-04
WO2003011893A2 (en) 2003-02-13
EP2191845A1 (en) 2010-06-02
EP1420821B1 (en) 2010-11-17
DE60238330D1 (de) 2010-12-30
US20040241182A1 (en) 2004-12-02
EP1420821B8 (en) 2011-02-02
US20030190324A1 (en) 2003-10-09
CA2454750C (en) 2012-09-18
EP1420821A2 (en) 2004-05-26
US7037509B2 (en) 2006-05-02
AU2002317604A1 (en) 2003-02-17
WO2003011893A3 (en) 2003-09-12
US6814969B2 (en) 2004-11-09
EP1420821A4 (en) 2006-08-30

Similar Documents

Publication Publication Date Title
ATE488249T1 (de) Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung
EP2011510A3 (en) Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
MX9702714A (es) Produccion de peptidos en plantas como fusiones de proteinas con revestimiento viral.
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
DE69434413D1 (de) Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
CA2111645A1 (en) Fibrinogen fragment e peptides and antibodies thereto
EP0965637A4 (en) Fas ANTIGEN DERIVATIVES
IL135687A0 (en) A novel human checkpoint kinase, hcds1, compositions and methods
PT1417222E (pt) Polipéptidos isolados baseados no epítopo neutralizante da proteína p17 de vih, úteis como vacinas, e anticorpos antip17 neutralizantes que reconhecem especificamente o referido polipéptido neutralizante
DE69233311D1 (de) Weidelgraspollen-allergen
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
PT635025E (pt) Processo para preparar proteinas modificadas
DE69128039D1 (de) Allergene aus roggenspreupollen
AU1444699A (en) Single-chain polypeptides comprising troponin i and troponin
ATE108802T1 (de) Polypeptidhemmer für virale replikation.
ATE312923T1 (de) Moraxella catarrhalis basb034 polypeptide und verwendungen davon
ATE234358T1 (de) Peptide des pferdearteritisvirus, antikörper und ihre verwendung in einem diagnostischen test
AU6393990A (en) Hiv related peptides
WO2000034294A3 (en) Tumor necrosis factor receptor homologue-1 ('trh1')
DE69827880D1 (de) Iga1-protease fragment als trägerpeptid
WO2001070774B1 (en) Human t cell response to mhc-binding motif clusters
NZ606260A (en) Novel polypeptides involved in immune response
MY106940A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties